Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Gliatech's Adcon-L

This article was originally published in The Gray Sheet

Executive Summary

Gliatech's Adcon-L: FDA's Orthopedic and Rehabilitation Devices Panel recommends approval of anti-adhesion product at a Dec. 12 meeting in Bethesda, Maryland. Adcon-L, a porcine-derived polymer gel, is indicated for use in reducing post-surgical peridural fibrosis (scar tissue that forms around the dura) and adhesions in posterior single-level (L4-L5 or L5-S1) laminectomy surgery. The nine committee members had differing opinions on whether data included in the firm's PMA supported proposed claims that the product reduced residual pain associated with peridural scarring despite data presented from the firm's European pivotal trial showing a statistically significant reduction in activity-related pain. Six-month results of the triple-blinded, multicenter, European trial, which included 267 available patients, showed that use of Adcon-L on patients compared to no treatment reduced by 12 percentage points (50% versus 38%) the number of patients with extensive scarring post-surgery. Efficacy was assessed by the amount of peridural scar found by a blinded neurologist on magnetic resonance imaging scans centered on the operated intervertebral space. U.S. clinical trials are still ongoing...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009267

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel